We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
HYMPAVZI (Pfizer Australia Pty Ltd)
Product name
HYMPAVZI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
173 (255 working days)
Active ingredients
marstacimab
Registration type
NCE/ NBE
Indication
Hympavzi is indicated for routine prophylaxis of bleeding episodes in patients 12 years of age and older with:
- severe haemophilia A (congenital factor VIII deficiency, FVIII <1%) without factor VIII inhibitors, or
- severe haemophilia B (congenital factor IX deficiency, FIX <1%) without factor IX inhibitors.